Long COVID Infections and Infestations
Conditions
Interventions
Once baseline data have been collected, the participants will be randomised. An independent statistician will perform the individual randomisation using a computer-generated random number sequence (bl
Sponsors
Instituto de Salud Carlos III
Instituto de Investigación Sanitaria Aragón
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. People with Long COVID 2. Over the age of 18 years 3. People cared for by Primary Care and belonged to scientific societies, associations or groups of Long COVID patients in Spain
Exclusion criteria
Exclusion criteria: 1. Presence of a serious uncontrolled medical illness that may interfere with compliance with the recommendations 2. Significant suicide risk 3. Pregnancy or lactation 4. Participation in another clinical trial in the last 6 months 5. Being receiving structured physiotherapeutic or psychotherapeutic treatment by a mental health professional 6. Presence of any medical, psychological or social problems that could seriously interfere with the patient's participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 13/02/2024: Quality of life assessed using the SF-36 Questionnaire at the beginning of the study and at the end of the intervention, that is, 3 months later. Previous primary outcome measure: Quality of life assessed using the SF-36 Questionnaire at the beginning of the study and at the end of the intervention, that is, approximately 2 or 3 months later | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Sociodemographic variables measured using a structured interview at the beginning of the study and at the end of the intervention, that is, approximately 2 or 3 months later 2. Clinical variables (time of evolution of Long COVID, number of residual symptoms and their intensity) measured using a structured interview at the beginning of the study and at the end of the intervention, that is, approximately 2 or 3 months later. The intensity of each symptom will be measured using a Visual Analog Scale 3. Self-efficacy measured using Sherer's General Self-Efficacy Scale (SGSES) at the beginning of the study and at the end of the intervention, that is, approximately 2 or 3 months later 4. Activation of the patient measured using Patient Activation Measure (PAM) at the beginning of the study and at the end of the intervention, that is, approximately 2 or 3 months later 5. Health literacy measured using the European Health Literacy Survey Questionnaire- short version (HLS-EU-Q16) at the beginning of the study and at the end of the intervention, that is, approximately 2 or 3 months later 6. Physical activity measured using the Physical Activity Questionnaire (IPAQ) at the beginning of the study and at the end of the intervention, that is, approximately 2 or 3 months later 7. Cognitive state measured using the Montreal Cognitive Assessment (MOCA) at the beginning of the study and at the end of the intervention, that is, approximately 2 or 3 months later 8. Emotional state measured using the Hospital Anxiety and Depression Scale (HADS) at the beginning of the study and at the end of the intervention, that is, approximately 2 or 3 months later 9. Sleep problems measured using the Insomnia Severity Index (ISI) at the beginning of the study and at the end of the intervention, that is, approximately 2 or 3 months later 10. Dyspnea and fatigue measured using the 30-second Sit and Stand up Test at the beginning of the study and at the end of the intervention, that is, approximatel | — |
Countries
Spain
Contacts
Public ContactSandra León-Herrera
Outcome results
None listed